33 research outputs found
Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity
Hepatitis C Virus (HCV) is a major public health concern, with no effective vaccines currently available and 3% of the world's population being infected. Despite the existence of both B- and T-cell immunity in HCV-infected patients, chronic viral infection and HCV-related malignancies progress. Here we report the identification of a novel HCV TCR from an HLA-A2-restricted, HCV NS3:1073–1081-reactive CTL clone isolated from a patient with chronic HCV infection. We characterized this HCV TCR by expressing it in human T cells and analyzed the function of the resulting HCV TCR-transduced cells. Our results indicate that both the HCV TCR-transduced CD4+ and CD8+ T cells recognized the HCV NS3:1073–1081 peptide-loaded targets and HCV+ hepatocellular carcinoma cells (HCC) in a polyfunctional manner with cytokine (IFN-γ, IL-2, and TNF-α) production as well as cytotoxicity. Tumor cell recognition by HCV TCR transduced CD8− Jurkat cells and CD4+ PBL-derived T cells indicated this TCR was CD8-independent, a property consistent with other high affinity TCRs. HCV TCR-transduced T cells may be promising for the treatment of patients with chronic HCV infections
Ethnoarchaeology: Implications of Ethnography for Archaeology. Carol Kramer, editor. Columbia University Press, New York, 1979. 292 pp. 70 illustrations (both line-cuts and photos), individual article bibliographies, editor's summaries for each article, topic index. $20.00.
6.64 AN INITIAL INVESTIGATION OF BRAIN FUNCTIONAL REORGANIZATION FOLLOWING ORGANIZATIONAL SKILLS TRAINING IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus
Respiratory infections caused by human rhinovirus are responsible
for severe exacerbations of underlying clinical conditions such as
asthma in addition to their economic cost in terms of lost working
days due to illness. While several antiviral compounds for treating
rhinoviral infections have been discovered, none have succeeded, to
date, in reaching approval for clinical use. We have developed a potent,
orally available rhinovirus inhibitor <b>6</b> that has progressed
through early clinical trials. The compound shows favorable pharmacokinetic
and activity profiles and has a confirmed mechanism of action through
crystallographic studies of a rhinovirus−compound complex.
The compound has now progressed to phase IIb clinical studies of its
effect on natural rhinovirus infection in humans
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus
Respiratory infections caused by human rhinovirus are responsible
for severe exacerbations of underlying clinical conditions such as
asthma in addition to their economic cost in terms of lost working
days due to illness. While several antiviral compounds for treating
rhinoviral infections have been discovered, none have succeeded, to
date, in reaching approval for clinical use. We have developed a potent,
orally available rhinovirus inhibitor <b>6</b> that has progressed
through early clinical trials. The compound shows favorable pharmacokinetic
and activity profiles and has a confirmed mechanism of action through
crystallographic studies of a rhinovirus−compound complex.
The compound has now progressed to phase IIb clinical studies of its
effect on natural rhinovirus infection in humans